Cytokinetics CEO Robert Blum Sells Shares Worth $575,700
On August 10, 2026, Cytokinetics' CEO, Robert I. Blum, sold 7,500 shares for a total of $575,700 as disclosed in an SEC Form 4 filing. The transaction involved the exercise of stock options at a strike price of $10.60 per share followed by immediate sale at a weighted average price of $76.76. Despite this sale, Blum still holds over 382,000 shares directly and indirectly through trusts, maintaining significant equity exposure in the company. Cytokinetics has a market capitalization of approximately $10.6 billion as of that date, with MYQORZO being its FDA-approved product for treating obstructive hypertrophic cardiomyopathy. The transaction appears to be part of routine financial activity rather than an indication of negative sentiment toward the company's prospects.
Tickers: $CYTK
Topics: Cytokinetics Robert I. Blum SEC Form 4 stock options